-Background -Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab in Latin American ulcerative colitis patients are scarce.Objective -To assess the clinical remission rates in induction and maintenance with adalimumab therapy in ulcerative colitis. Declared conflict of interest of all authors: Damião AOMC (Nestle, Janssen, Abbvie, Pfizer and Takeda), Moraes AC (Janssen, Abbvie, Takeda), Teixeira FV (Janssen, Abbvie, Ferring, Takeda, Pfizer), Ludvig JC (Janssen, Abbvie, Takeda), Nones RB (Abbvie, Takeda), Saad-Hossne R (Janssen, Abbvie), Sassaki LY (Janssen, Abbvie, Takeda), Kotze PG (Janssen, Abbvie, Ferring, Takeda, Pfizer The rate of colectomy in ULTRA II trial was less than 5%, without stratification regarding the previous use of another anti-TNF agent (8) . The drug was approved by Food and Drug Administration (FDA) and National Sanitary Surveillance Agency (ANVISA), in 2012 and 2014, respectively (14) . Despite the results of the clinical trials, there is a discrepancy between those and real world data in UC (15) , similar to what was observed in terms of efficacy of ADA in Crohn's disease (CD) (13) . Retrospective studies of case series tend to have higher effectiveness rates than randomized trials, which have a more strict analysis. Furthermore, it is enquired what the ideal dose of ADA in the management of UC would be needed (12) , showing the need of data from real life studies to better define the drug's role in treatment algorithms. There is scarce real world data on the use of ADA in UC reported in Brazil and Latin America, which motivated the present study (1,2,9,10,18,28,29) . The primary aim of this study was to analyze clinical remission rates in ADA induction and maintenance in UC treatment. Secondary objectives were to analyze clinical response, endoscopic remission, colectomy rates, adverse events, and secondary loss of response, besides dose optimization or drug switching during the follow-up period. Adalimumab for ulcerative colitis: results of a Brazilian multicenter observational study METHODS Study designThis was a longitudinal, analytical, observational and retrospective study of a case series of patients with moderate-to-severe UC under ADA therapy. All patients were treated in seven referral centers for inflammatory bowel disease (IBD) from south/southeast Brazil, and were analyzed from

Introduction Ileocolic resection (ICR) is the most common surgical procedure performed for Crohn's disease (CD). Similarly, right-sided Colorectal cancer (CRC) is treated by the same operation. The primary aim of this study was to analyze and compare the frequency and profile of early postoperative complications of ICR between patients with CD and CRC. Methods Retrospective and observational study with patients submitted to ICR from two Brazilian tertiary referral units in colorectal surgery. We included patients with diagnosis of CD or CRC, treated with ICR, at any stage of follow-up. Variables analyzed: age at surgery, gender, diagnosis, surgical approach (open or laparoscopy), type of anastomosis (hand-sewn/stapled; end-to-end/side-to-side), presence and type of early postoperative complications (30 days) and mortality, among others. Results 109 patients were included, 73 with CD (67%) and 36 with CRC (33%). CD patients were younger (42.44 ± 12.73 years vs. 66.14 ± 11.02 years in the CRC groups, p < 0.0001) and had more previous resections (20 ± 27.4 in CD and 0 in CCR, p = 0.001). There were no significant differences between the groups in terms of overall early postoperative complications [17/73 (23.3%) in the CD and 5/36 (13.9%) in the CRC groups (p = 0.250)]. There was no significant difference between the groups in relation to anastomotic leakage (p = 0.185), surgical site infections (p = 0.883), other complications (0.829) and deaths (p = 0.069). Conclusions There was no significant difference in early postoperative complications in patients with CD or CRC submitted to ICR.